Therapeutic Drug Targets and Phytomedicine For Triple Negative Breast Cancer

Pre-Clinical and Clinical Evidence of Recent Therapeutic Trends and Spotting Possibility of Cure in Near Future

Author(s): Amitha Muraleedharan, Sagar Kumar and Rashmi Mittal * .

Pp: 73-98 (26)

DOI: 10.2174/9789815079784123010007

* (Excluding Mailing and Handling)


Substantial cohort studies, pre-clinical, clinical trials, and in-depth genomic and proteomic analysis underlie that several molecular alterations exist in TNBC that may be favorable or detrimental to cancer progression. Molecular heterogeneity in TNBC has shortened the disease-free survival rate in response to adjuvant and neoadjuvant therapies. To determine possible vulnerabilities in TNBC, several drugs were under investigation. This chapter highlighted the current paradigm of the therapeutic approach including surgery, radiotherapy, and chemotherapy. In this review, we also highlighted the clinical trials involved in the management of TNBC by targeting angiogenesis, apoptosis, androgen receptors, cell cycle, and pro-survival signalling pathways. To overcome the constraints associated with the mono-therapeutic approach, pre-clinical and clinical studies of combinational therapy have also been discussed to improve OS, DFS, and DMFS in TNBC patients. 

Keywords: Androgen receptors, Anti-angiogenesis, Apoptosis, CDK inhibitors, Chemotherapy, Clinical trials, Combinational therapy, Immunomodulatory agents, Loco regional treatment, Monotherapy, Pre-clinical, Radiotherapy, Surgery.

Related Journals
Related Books
© 2024 Bentham Science Publishers | Privacy Policy